

Plos one

A multi-database based ceRNA regulatory network for gastric cancer prognosis

Long-Kuan Yin¹, Qian Li^{*2}

1. Department of Gastrointestinal Surgery, People's Hospital of Fushun County ,Zigong 643200, Sichuan Province, China
2. Department of Oncology, Fushun Hospital of Traditional Chinese Medicine, Zigong 643200, Sichuan Province, China

Long-Kuan Yin, Department of Gastrointestinal Surgery, People's Hospital of Fushun County 643200,Zigong , Sichuan Province, China

Qian Li, Department of Oncology, Fushun Hospital of Traditional Chinese Medicine, Zigong 643200, Sichuan Province, China

ORCID number: Long-Kuan Yin(0000-0001-5974-5443);Qian Li (0009-0006-9250-0521)

Telephone: +86-813-7190019 **Fax:**+86-813-7190019

Author contributions: Yin LK contributed to this work. Yin LK, Qian L prepared for the figures and tables; and all authors have approved the final manuscript.

***Corresponding author:** Qian Li, MD, Doctor, Professor, Department of Gastrointestinal Surgery, People's Hospital of Fushun County, No. 116, Fuda Road, Fushi Town, Zigong 643200, Sichuan Province, China. 343893613@qq.com

Abstract:

Objective: Circular RNA(circRNA) is a kind of endogenous non-coding RNA, which may be related to the occurrence and development of cancer. Based on the GEO database, this paper constructs a circRNA as a competitive endogenous RNAs(ceRNAs) that binds with microRNAs (miRNAs) to affect and regulate the expression of target genes. The ceRNA regulatory network based on circRNA-miRNA-mRNA model plays an important role in tumor prognosis and treatment. This paper explores the mechanism of circRNA-related ceRNA regulatory network in gastric cancer.

Method: CircRNA, miRNA and mRNA data sets related to gastric cancer were downloaded from The Gene Expression Omnibus (GEO), and the limma package of R software ([R 4.2.1 version](#)) was used to identify the differences between gastric cancer tissues and adjacent normal tissues of gastric cancer. DEcircRNA, DEmiRNAs, and DEMRNAs. Based on circBase database, we explored the interactions among circRNA, miRNA and mRNA, and constructed the circRNA-miRNA-mRNA ceRNA network by using [Cytoscape_v3.8.0](#). Then KEGG, GO and survival analysis of ceRNA-related genes were

performed. Then, the prognostic data of gastric cancer were extracted from the TCGA database to construct the prognostic subnetwork of gastric cancer.

Results: KEGG analysis of ceRNA's mRNA showed that the pathway was mainly enriched in IL-17 signaling pathway, TNF signaling pathway and so on, which affected the prognosis of gastric cancer. hsa_circ_0055521/hsa-miR-204-5p/FAP, (hsa_circ_0005051, hsa_circ_0007613, hsa_circ_0045602, hsa_circ_0034398, hsa_circ_0006089) /hsa-miR-32-3p/FNDC1 were the ceRNA networks related to the prognosis of gastric cancer collaterals.

Conclusion: This study found that IL-17 signaling pathway and TNF signaling pathway may affect the occurrence, development and prognosis of gastric cancer. And hsa_circ_0055521/hsa-miR-204-5p/FAP, (hsa_circ_0005051, hsa_circ_0007613, hsa_circ_0045602, hsa_circ_0034398, hsa_circ_0006089) /hsa-miR-32-3p/FNDC1 two circRNA-based stomachs The cancer ceRNA prognostic network is a new prognostic related ceRNA network for gastric cancer. FNDC1 and FAP may be potential therapeutic targets for gastric cancer.

Key words: circRNA, miRNA, therapeutic target, gastric cancer,

prognosis.

1. Introduction

Gastric cancer (GC), as a common global cause of cancer death [1-3], is most frequently found in East Asia, such as South Korea, China and Japan[4,5] and so on. The early clinical symptoms of gastric cancer lack specificity [6-8], which leads to the late diagnosis of most gastric cancer patients[9]. Although the diagnosis and treatment strategies for gastric cancer have gradually increased in recent decades, the treatment effectiveness of advanced gastric cancer is poor, and the prognosis of patients remains poor[10-12]. The complexity and multi-factor nature of pathogenic factors, occurrence, development and metastasis mechanism of gastric cancer make the treatment of gastric cancer more difficult and complicated. Patients with advanced gastric cancer have a lower 5-year survival rate[13]. Therefore, there is an urgent need to find more therapeutic targets to improve diagnosis and treatment measures to improve the survival and prognosis of patients.

In recent years, with the development of gene technology, we have found that there are very rich regulatory modes of various Rnas in cells, and ceRNA regulation is one of the more studied regulatory modes. ceRNA

refers to a new mechanism of RNA interaction in which mRNA, lncRNA, circRNA, etc. regulate each other at the post-transcriptional level through competition and sharing of miRNA[14].

CircRNAs are a class of covalently closed single-stranded RNA molecules that exist widely in eukaryotic cells. circRNA is a class of regulatory molecules with various functions, which can play functions such as regulating gene expression, binding miRNA or protein, and translating into protein, etc. CircRNA may be of great significance for cell proliferation, cell differentiation, individual growth and development, and may be related to the occurrence and development of cancer [15,16]. Based on the GEO database, this paper constructs a circRNA as a competitive endogenous RNAs(ceRNAs) that binds with microRNAs (miRNAs) to affect and regulate the expression of target genes. The ceRNA regulatory network based on circRNA-miRNA-mRNA model plays an important role in tumor prognosis and treatment. This paper explores the mechanism of circRNA-related ceRNA regulatory network in gastric cancer.

CircRNA, miRNA and mRNA data sets related to gastric cancer were downloaded from The Gene Expression Omnibus (GEO)[17] and limma package of R software (R 4.2.1 version) was used to identify the

relationship between gastric cancer tissue and adjacent normal tissue.

Differentially expressed circRNA (DEcircRNA), differentially expressed miRNAs (DEmiRNAs) and differentially expressed mRNAs (DEmRNAs). We analyzed the relationship between Rnas based on circBase database, and constructed a ceRNA network using circRNA-miRNA-mRNA template by using Cytoscape_v3.8.0. Then, the target genes of ceRNA were analyzed by KEGG[18], GO[19]and survival analysis. The mRNA expression and clinical data related to gastric Cancer were extracted from The Cancer Genome Atlas[20] (TCGA) database, and the survival data of gastric cancer were extracted. Then, combined with the relevant gastric cancer data of TCGAand GEO databases, we explored the potential relationship between circRNA, miRNA and mRNA and the prognosis of gastric cancer, searched for new potential ceRNA regulatory networks, and searched for potential therapeutic targets through this network.

2. Materials and methods

2.1 Data download and processing

Downloaded from GEO database (<https://www.ncbi.nlm.nih.gov/geo/>) gastric cancer related [GSE83521](#) circRNA dataset, the miRNA [GSE93415](#) data sets, mRNA [GSE118916](#) data sets.

2.2 Difference analysis was conducted on circRNA, miRNA and mRNA data respectively.

Firstly, the difference analysis of circRNA, miRNA and mRNA was carried out respectively, and the heat map analysis of circRNA, miRNA and mRNA with significant differences was carried out respectively.

2.3 CircRNA, miRNA and mRNA of ceRNA network were extracted and the ceRNA network diagram was constructed.

First, the structure diagram of circRNA and the set MRE of reaction elements were found through circBase database. The intersection of mirna.diff and MRE is made by Venn diagram. The target file was obtained by predicting the target gene of the co-expressed micRNA, and the target and mRNA. diff files were processed by venn using R software ([R 4.2.1 version](#)) to search for the co-expressed mRNA. Then prepare MRE, mrnas.diff, target, mirna.diff, circ.diff files respectively, and use Perl software to process each file. The files ceRNA.network, ceRNA.node, ceRNA.circList, ceRNA.mirnaList, and cerna.mrnalist are obtained respectively. Finally, the ceRNA network diagram is established using Cytoscape [3.8.0](#).

2.4 The expression differences of circRNA, miRNA and mRNA between gastric cancer tissues and adjacent normal tissues were analyzed.

Heat map analysis and boxplot analysis of ceRNA's RNA expression between tumor tissue and normal tissue.

2.5 mRNA in ceRNA network was analyzed by GO and KEGG.

mRNA in ceRNA network was analyzed by GO and KEGG to find the possible signaling pathway.

2.6 Gastric cancer expression data and clinical data were extracted from the TCGA database for survival analysis.

Will be extracted from TCGA database (<https://portal.gdc.cancer.gov/>) of gastric cancer expression data sorting for expressing, extract gastric cancer clinical data. The gastric cancer expression profile was combined with clinical data for survival analysis.

2.7 Gastric cancer data of TCGA and GEO databases were merged.

The expression index and clinical data of gastric cancer extracted from TCGA database and RNA from ceRNA network from GEO database were combined to obtain the survival data of ceRNA network. We then performed ceRNA survival analysis.

2.8 Construct ceRNA network diagram related to prognosis of gastric cancer.

Based on the above data, we constructed a prognostic correlation network map for gastric cancer.

2.9 Protein immunohistochemical analysis was performed by HPA.

Protein immunohistochemical analysis of prognostic ceRNA network mRNA was performed using HPA database.

2.10 Statistical analysis. All statistical analyses were performed using R software. $P < 0.05$ was considered statistically significant.

3. Results

3.1 Differences of circRNA, miRNA and mRNA were analyzed respectively.

We found 24 significantly different circRNAs, 91 significantly different miRNAs, and 114 significantly different mRNAs through difference analysis. Through heat map analysis, we found 24 significantly different circRNAs with low expression in normal tissues and almost high expression in tumor tissues (Figure 1, A). The expression of 38 miRNAs was high in normal tissues and low in tumor tissues. Fifty-three miRNAs were expressed in normal tissues and highly expressed in tumor tissues (Figure 1, B). 82 mRNA were highly expressed in normal tissues and low expressed in tumor tissues. 32 mRNAs were low expressed in normal

tissues and high expressed in tumor tissues (Figure 1,C).

3.2 The circRNA structure diagram (Figure 2.1-2.2) and the set MRE of reaction elements were searched through circBase database. miRNA.diff and MRE were intersected by Venn diagram (Figure 2.3, A). The target file was obtained by predicting the target gene of the co-expressed micRNA, and the target and mRNA. diff files were processed by venn using R software (R 4.2.1 version) to find the co-expressed mRNA (Figure 2.3, B). Then prepare MRE, mRNAs.diff, target, miRNA.diff, circRNA.diff files respectively, and use Perl software to process each file. The files ceRNA.network, ceRNA.node, ceRNA.circList, ceRNA.mirnaList, and ceRNA.mrnalist are obtained respectively. Finally, the ceRNA network diagram is constructed with Cytoscape 3.8.0. We found that 13 circRNAs, 11 miRNAs, and 15 mRNAs formed the ceRNA network nodes. The ceRNA network diagram (Figure 2.3) was constructed.

3.3 Through heat map analysis of circRNA, miRNA and mRNA that constitute ceRNA network, it can be found that 13 circRNAs have low expression in normal samples and high expression in tumor samples. The expression of 11 miRNAs was high in normal samples and low in tumor samples. The expression of 15 mRNA was low in normal samples and

high in tumor samples. A ceRNA network diagram is constructed (Figure 3).

3.4 Through the analysis of heat maps (Figure 4.1A, B, Figure 4.2) and box plots (Figure 4.3-4.4) of circRNA, miRNA and mRNA constituting ceRNA network, it can be found that there are differences in circRNA, miRNA and mRNA between tumor tissues and normal tissues.

3.5 GO (Figure 5.1-5.3, table 1-3) and KEGG (Figure 5.4, table 4) analyses were performed on mRNA constituting the ceRNA network. In this study, it was found that the main pathways were enriched in IL-17 signaling pathway and TNF signaling pathway.

3.6 Establishment of ceRNA network related to the prognosis of gastric cancer.

Survival data extracted from the TCGA database were combined with ceRNA data to obtain the ceRNA network related to the prognosis of gastric cancer. hsa_circ_0055521/hsa-miR-204-5p/FAP, (hsa_circ_0005051, hsa_circ_0007613, hsa_circ_0045602, hsa_circ_0034398, hsa_circ_0006089) /hsa-miR-32-3p/FNDC1 (Figure 6.1). Then, survival analysis of FAP and FNDC1 genes was performed, $P < 0.05$ (Figure 6.2).

3.7 Immunohistochemical analysis.

We through the human protein map (the human protein atlas, HPA), org (<https://www.proteinatlas.org>) network database of FNDC1, FAP this two may affect the prognosis of gastric cancer gene independently, immunohistochemical analysis, The comparison of protein expression of FNDC1 and FAP in gastric cancer tissue and adjacent normal tissue showed significant differences in protein expression of FNDC1 and FAP in gastric cancer tissue and adjacent normal tissue respectively (Figure 7).

4. Discussion

At present, non-coding RNA (ncRNA) can be divided into microRNAs (miRNAs), long non-coding RNAs (lncRNAs), circular RNAs (circRNAs) and PIWI interacting RNAs (piRNAs) according to their length, shape and location. As a functional regulatory molecule mediating cellular processes such as chromatin remodeling, transcription, post-transcriptional modification, and signal transduction; The networks in which ncRNAs participate can influence numerous molecular targets to drive specific cellular biological responses and fates, which in turn influence the development and progression of tumors[21,22]. Based on the analysis of gastric cancer data from TCGA and GEO sources, this study explored the ceRNA network composed of circRNAs that may affect the prognosis of gastric cancer and its possible mechanism.

In this study, circRNA, miRNA and mRNA with significant differences in expression between gastric cancer tissues and adjacent normal tissues of gastric cancer were first screened, and the circRNA reaction originals and related mRNA were screened. A new circRNA-based ceRNA network diagram was then constructed. Through GO and KEGG analysis of ceRNA target genes, we found that their main functions were enriched in IL-17 signaling pathway and TNF signaling pathway. Therefore, our study found that these two pathways may be related to the occurrence and development of gastric cancer.

There have been many studies on the role of inflammatory factors in cancer, and this article will not elaborate on them. In terms of IL-17 signaling pathway, this study shows that it may affect the occurrence and development of gastric cancer. Of course, the specific mechanism needs further experimental verification. Previous studies have found that it may promote tumor progression, growth and migration of tumor cells by changing the tumor micro-environment, leading to poor prognosis in patients with gastric cancer[23,24]. Studies of gene network pharmacology have found that IL-17 signaling pathway may be associated with gastric cancer [25]. Previous experimental studies have found that IL-17 may affect the occurrence and development of gastric

cancer by regulating Beclin-1 ubiquitination and autophagy[26]. As for the study of TNF signaling pathway, previous studies have found that TNF may affect the micro-environment of gastric carcinoma and the development of gastric cancer[27]. It has also been found that TNF may influence the progression of gastric cancer through signaling mediated epithelial-stromal interaction[28]. These studies further indicate that IL-17 signaling pathway and TNF signaling pathway may affect the development and prognosis of gastric cancer from various aspects.

Two sub-networks related to the prognosis of gastric cancer were screened through prognostic data: hsa_circ_0055521/hsa-miR-204-5p/FAP, (hsa_circ_0005051, hsa_circ_0007613, hsa_circ_0045602, hsa_circ_0034398, hsa_circ_0006089) /hsa-miR-32-3p/FNDC1. Different from previous studies, these two prognostic related ceRNA networks are new circRNA-based prognostic related ceRNA networks for gastric cancer. Through circbase database, we found that the target gene of hsa_circ_0055521 is circ MRPL35, and circ MRPL35 gene has been found in previous studies to inhibit the proliferation of gastric cancer cells [29,30]. The FAP gene identified in this study has no correlation with hsa_circ_0055521 reported in previous studies. However, this study found that hsa_circ_0055521 may regulate the expression of FAP through

sponging action on hsa-miR-204-5p, thus regulating the occurrence and development of gastric cancer. It can affect the prognosis of gastric cancer. Through geneCards, we found that FAP is mainly associated with invasive basal cell carcinoma and melanoma. At present, studies have also found that FAP may be related to drug resistance, prognosis and peritoneal metastasis of gastric cancer[31,32]. In the second CircrNa-based gastric cancer prognostic network in this study, it was found that circUBXN7, circPRRC2B, circHN1, circC15orf41 and circASAP2 could regulate the expression of FNDC1 through competitive sponging of hsa-miR-32-3p. It can affect the occurrence, development and prognosis of gastric cancer. Through the screening of previous studies, we found that there are few studies on the effects of circUBXN7 on tumor prognosis, and only the effects of circUBXN7 on the proliferation, migration and inhibition of apoptosis of hepatocellular carcinomas [33]. However, the effect on prognosis of gastric cancer has not been reported. Similarly, for the effect of circPRRC2B in tumors, we found that it may be relevant to the development and survival of patients with nephroblastoma[34]. However, studies on its relationship with gastric cancer and other tumors have not yet found, but this study found that it may be related to the prognosis of gastric cancer. For circHN1, we found that some studies have found an association with the progression of gastric cancer [35-37]. However, there are few studies, which can be used

as the direction of further research on the occurrence and development of gastric cancer. Studies on the relationship between circC15orf41 and the occurrence and development of gastric cancer have not yet been found, but we have found through previous studies that it may be related to the metastasis of osteosarcomatus[38]. This also provides a new direction for us to explore the road of gastric cancer treatment. This study found that circASAP2 may be related to the prognosis of gastric cancer, and some previous studies on this aspect have also confirmed that circasap2 may affect the drug resistance and prognosis of gastric cancer [39-42], and of course may also affect the occurrence and development of pancreatic cancer [43]. However, the specific mechanism of its influence on the occurrence, development and prognosis of gastric cancer is not fully understood and needs further exploration. Regarding the second target gene FNDC1 discovered in this study, current studies on its relationship with gastric cancer mainly focus on the possibility that its high expression may be associated with poor prognosis of gastric cancer, but the specific mechanism remains to be further explored [44-48]. Through the above studies, it was found that circUBXN7, circPRRC2B, circHN1, circC15orf41, circASAP2, FNDC1 and FAP may affect the prognosis of gastric cancer, and the specific mechanism needs to be further studied.

Finally, we conducted immunohistochemical analysis of the proteins of

the two target genes identified in this study through the HPA database, and we found that there were significant differences in the protein expressions of FNDC1 and FAP in cancer tissues and adjacent normal tissues. These two genes, FNDC1 and FAP, may affect the occurrence and development of gastric cancer and the prognosis of gastric cancer.

5. Conclusion

In summary, this study found that IL-17 signaling pathway and TNF signaling pathway may affect the occurrence, development and prognosis of gastric cancer. And hsa_circ_0055521/hsa-miR-204-5p/FAP, (hsa_circ_0005051, hsa_circ_0007613, hsa_circ_0045602, hsa_circ_0034398, hsa_circ_0006089) /hsa-miR-32-3p/FNDC1 two circRNA-based stomachs The cancer ceRNA prognostic network is a new prognostic related ceRNA network for gastric cancer. FNDC1 and FAP may be potential therapeutic targets for gastric cancer.

ARTICLE HIGHLIGHTS

Research background

Gastric cancer (GC) is one of the most common malignant tumors, and its pathogenesis are still unclear.

Research motivation

The present study for the first time investigated the multi-database based ceRNA regulatory network for gastric cancer prognosis using bioinformatics.

Research objectives

The aims of this study are to explore the multi-database based ceRNA regulatory network for gastric cancer prognosis, so as to provide new strategies for the treatment of GC.

Research methods

In this study, bioinformatics strategy was used to obtain Datasets from The Cancer Genome Atlas, Gene Expression Omnibus and Gene Expression Profiling Interactive Analysis. The software of R software, circBase and Human Protein Atlas, were performed to analyze and integrate the mRNA datasets, respectively.

Research results

KEGG analysis of ceRNA's mRNA showed that the pathway was mainly enriched in IL-17 signaling pathway, TNF signaling pathway and so on, which affected the prognosis of gastric cancer. hsa_circ_0055521/hsa-miR-204-5p/FAP, (hsa_circ_0005051, hsa_circ_0007613, hsa_circ_0045602, hsa_circ_0034398, hsa_circ_0006089) /hsa-miR-32-3p/FNDC1 were the ceRNA networks related to the prognosis of gastric cancer collaterals.

Research conclusions

This study found that IL-17 signaling pathway and TNF signaling pathway may affect the occurrence, development and prognosis of gastric cancer. And hsa_circ_0055521/hsa-miR-204-5p/FAP, (hsa_circ_0005051, hsa_circ_0007613, hsa_circ_0045602, hsa_circ_0034398, hsa_circ_0006089) /hsa-miR-32-3p/FNDC1 two circRNA-based stomachs cancer ceRNA prognostic network is a new prognostic related ceRNA network for gastric cancer. FNDC1 and FAP may be potential therapeutic targets for gastric cancer.

Research perspectives

The two circRNA-based stomachs cancer ceRNA prognostic network is a new prognostic related ceRNA network for gastric cancer, which needs further confirmation through

molecular biology and clinical experiments.

6. References

- 1 Li, Y. *et al.* Single-cell landscape reveals active cell subtypes and their interaction in the tumor microenvironment of gastric cancer. *Theranostics* **12**, 3818-3833, doi:10.7150/thno.71833 (2022).
- 2 Chang, X., Ge, X., Zhang, Y. & Xue, X. The current management and biomarkers of immunotherapy in advanced gastric cancer. *Medicine* **101**, e29304, doi:10.1097/md.0000000000029304 (2022).
- 3 Zhang, Y. & Yu, J. The role of MRI in the diagnosis and treatment of gastric cancer. *Diagnostic and interventional radiology (Ankara, Turkey)* **26**, 176-182, doi:10.5152/dir.2019.19375 (2020).
- 4 Wu, S. L., Zhang, Y., Fu, Y., Li, J. & Wang, J. S. Gastric cancer incidence, mortality and burden in adolescents and young adults: a time-trend analysis and comparison among China, South Korea, Japan and the USA. *BMJ open* **12**, e061038, doi:10.1136/bmjopen-2022-061038 (2022).
- 5 Yang, X. *et al.* Temporal trend of gastric cancer burden along with its risk factors in China from 1990 to 2019, and projections until 2030: comparison with Japan, South Korea, and Mongolia. *Biomarker research* **9**, 84, doi:10.1186/s40364-021-00340-6 (2021).
- 6 Titov, S. E. *et al.* [Differential diagnostics of gastric cancer and precancerous changes of the gastric mucosa using analysis of expression of six microRNAs.]. *Klinicheskaia laboratornaia diagnostika* **65**, 131-136, doi:10.18821/0869-2084-2020-65-2-131-136 (2020).
- 7 Tong, H. *et al.* Volatile organic metabolites identify patients with gastric carcinoma, gastric ulcer, or gastritis and control patients. *Cancer cell international* **17**, 108, doi:10.1186/s12935-017-0475-x (2017).
- 8 Zhao, Y. *et al.* A potential role of collagens expression in distinguishing between premalignant and malignant lesions in stomach. *Anatomical record (Hoboken, N.J. : 2007)* **292**, 692-700, doi:10.1002/ar.20874 (2009).
- 9 Kondo, A. *et al.* Endoscopy vs surgery in the treatment of early gastric cancer: Systematic review. *World journal of gastroenterology* **21**, 13177-13187, doi:10.3748/wjg.v21.i46.13177 (2015).
- 10 Xiang, Z. *et al.* Identification of the ferroptosis-related ceRNA network related to prognosis and tumor immunity for gastric cancer. *Aging* **14**, 5768-5782, doi:10.18632/aging.204176 (2022).
- 11 White, J. R. & Banks, M. Identifying the pre-malignant stomach: from guidelines to practice. *Translational gastroenterology and hepatology* **7**, 8, doi:10.21037/tgh.2020.03.03 (2022).
- 12 Sukri, A., Hanafiah, A. & Kosai, N. R. The Roles of Immune Cells in Gastric Cancer: Anti-Cancer or Pro-Cancer? *Cancers* **14**, doi:10.3390/cancers14163922 (2022).
- 13 Afrash, M. R., Shanbehzadeh, M. & Kazemi-Arpanahi, H. Design and Development of an Intelligent System for Predicting 5-Year Survival in Gastric Cancer. *Clinical Medicine Insights. Oncology* **16**, 11795549221116833, doi:10.1177/11795549221116833 (2022).
- 14 Qi, X. *et al.* ceRNA in cancer: possible functions and clinical implications. *Journal of medical*

- 15 Kristensen, L. S., Jakobsen, T., Hager, H. & Kjems, J. The emerging roles of circRNAs in cancer and oncology. *Nature reviews. Clinical oncology* **19**, 188-206, doi:10.1038/s41571-021-00585-y (2022).
- 16 Chen, L. & Shan, G. CircRNA in cancer: Fundamental mechanism and clinical potential. *Cancer letters* **505**, 49-57, doi:10.1016/j.canlet.2021.02.004 (2021).
- 17 Barrett, T. *et al.* NCBI GEO: archive for functional genomics data sets--update. *Nucleic acids research* **41**, D991-995, doi:10.1093/nar/gks1193 (2013).
- 18 Kanehisa, M. & Goto, S. KEGG: kyoto encyclopedia of genes and genomes. *Nucleic acids research* **28**, 27-30, doi:10.1093/nar/28.1.27 (2000).
- 19 Gene Ontology Consortium: going forward. *Nucleic acids research* **43**, D1049-1056, doi:10.1093/nar/gku1179 (2015).
- 20 Tomczak, K., Czerwińska, P. & Wiznerowicz, M. The Cancer Genome Atlas (TCGA): an immeasurable source of knowledge. *Contemporary oncology (Poznan, Poland)* **19**, A68-77, doi:10.5114/wo.2014.47136 (2015).
- 21 Yan, H. & Bu, P. Non-coding RNA in cancer. *Essays in biochemistry* **65**, 625-639, doi:10.1042/ebc20200032 (2021).
- 22 Anastasiadou, E., Jacob, L. S. & Slack, F. J. Non-coding RNA networks in cancer. *Nature reviews. Cancer* **18**, 5-18, doi:10.1038/nrc.2017.99 (2018).
- 23 Bie, Q. *et al.* Non-tumor tissue derived interleukin-17B activates IL-17RB/AKT/ β -catenin pathway to enhance the stemness of gastric cancer. *Scientific reports* **6**, 25447, doi:10.1038/srep25447 (2016).
- 24 Bastid, J., Dejoui, C., Docquier, A. & Bonnefoy, N. The Emerging Role of the IL-17B/IL-17RB Pathway in Cancer. *Frontiers in immunology* **11**, 718, doi:10.3389/fimmu.2020.00718 (2020).
- 25 Han, L. & Han, Y. Network Pharmacology-Based Study on the Active Component and Mechanism of the Anti-Gastric-Cancer Effect of Herba Sarcandrae. *Journal of healthcare engineering* **2021**, 3001131, doi:10.1155/2021/3001131 (2021).
- 26 Bie, Q. *et al.* IL-17B/IL-17RB signaling cascade contributes to self-renewal and tumorigenesis of cancer stem cells by regulating Beclin-1 ubiquitination. *Oncogene* **40**, 2200-2216, doi:10.1038/s41388-021-01699-4 (2021).
- 27 Qu, Y. *et al.* The effects of TNF- α /TNFR2 in regulatory T cells on the microenvironment and progression of gastric cancer. *International journal of cancer* **150**, 1373-1391, doi:10.1002/ijc.33873 (2022).
- 28 Zhou, Q. *et al.* The reciprocal interaction between tumor cells and activated fibroblasts mediated by TNF- α /IL-33/ST2L signaling promotes gastric cancer metastasis. *Oncogene* **39**, 1414-1428, doi:10.1038/s41388-019-1078-x (2020).
- 29 Yuan, L. *et al.* 18 β -glycyrrhetic acid regulates mitochondrial ribosomal protein L35-associated apoptosis signaling pathways to inhibit proliferation of gastric carcinoma cells. *World journal of gastroenterology* **28**, 2437-2456, doi:10.3748/wjg.v28.i22.2437 (2022).
- 30 Yuan, L. *et al.* Depletion of MRPL35 inhibits gastric carcinoma cell proliferation by regulating downstream signaling proteins. *World journal of gastroenterology* **27**, 1785-1804, doi:10.3748/wjg.v27.i16.1785 (2021).
- 31 Tong, Y., Zhao, Z., Zhang, J., Wang, W. & Zhu, Y. High expressions of CD10, FAP and

- GPR77 in CAFs are associated with chemoresistance and worse prognosis in gastric cancer. *Frontiers in oncology* **12**, 984817, doi:10.3389/fonc.2022.984817 (2022).
- 32 Wu, H. *et al.* BGN/FAP/STAT3 positive feedback loop mediated mutual interaction between tumor cells and mesothelial cells contributes to peritoneal metastasis of gastric cancer. *International journal of biological sciences* **19**, 465-483, doi:10.7150/ijbs.72218 (2023).
- 33 Yao, J. N. *et al.* [Circular RNA-UBXN7 promotes proliferation, migration and suppresses apoptosis in hepatocellular cancer]. *Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology* **28**, 421-427, doi:10.3760/cma.j.cn501113-20200305-00086 (2020).
- 34 He, S., Yang, L., Xiao, Z., Tang, K. & Xu, D. Identification of key carcinogenic genes in Wilms' tumor. *Genes & genetic systems* **96**, 141-149, doi:10.1266/ggs.21-00015 (2021).
- 35 Zhang, M. & Jiang, Y. Downregulation of circular RNA circ-HN1 suppressed the progression of gastric cancer through the miR-485-5p/GSK3A pathway. *Bioengineered* **13**, 5675-5684, doi:10.1080/21655979.2021.1987124 (2022).
- 36 Zhang, J., Wang, F., Zhang, H. & Cao, M. A novel circular RNA circ_HN1/miR-628-5p/Ecto-5'-nucleotidase competing endogenous RNA network regulates gastric cancer development. *Bioengineered* **12**, 9739-9752, doi:10.1080/21655979.2021.1989259 (2021).
- 37 Wang, D. *et al.* Circular RNA circ_HN1 facilitates gastric cancer progression through modulation of the miR-302b-3p/ROCK2 axis. *Molecular and cellular biochemistry* **476**, 199-212, doi:10.1007/s11010-020-03897-2 (2021).
- 38 Yan, C. F. *et al.* Tumor-associated macrophages-derived exo-let-7a promotes osteosarcoma metastasis via targeting C15orf41 in osteosarcoma. *Environmental toxicology* **38**, 1318-1331, doi:10.1002/tox.23766 (2023).
- 39 Hu, J. *et al.* Arsenic sulfide inhibits the progression of gastric cancer through regulating the circRNA_ASAP2/Wnt/ β -catenin pathway. *Anti-cancer drugs* **33**, e711-e719, doi:10.1097/cad.0000000000001246 (2022).
- 40 Sun, Y. *et al.* Circular RNA circ_ASAP2 regulates drug sensitivity and functional behaviors of cisplatin-resistant gastric cancer cells by the miR-330-3p/NT5E axis. *Anti-cancer drugs* **32**, 950-961, doi:10.1097/cad.0000000000001087 (2021).
- 41 Lin, D., Lin, X., He, T. & Xie, G. Gambogic Acid Inhibits the Progression of Gastric Cancer via circRNA_ASAP2/miR-33a-5p/CDK7 Axis. *Cancer management and research* **12**, 9221-9233, doi:10.2147/cmar.s269768 (2020).
- 42 Chen, B., Ji, F., Wen, X. & Jin, Z. Circular RNA circ_ASAP2 promotes cell viability, migration, and invasion of gastric cancer cells by regulating the miR-770-5p/CDK6 axis. *International journal of clinical and experimental pathology* **13**, 2806-2819 (2020).
- 43 Fujii, A. *et al.* The novel driver gene ASAP2 is a potential druggable target in pancreatic cancer. *Cancer science* **112**, 1655-1668, doi:10.1111/cas.14858 (2021).
- 44 Wu, K. Z., Xu, X. H., Zhan, C. P., Li, J. & Jiang, J. L. Identification of a nine-gene prognostic signature for gastric carcinoma using integrated bioinformatics analyses. *World journal of gastrointestinal oncology* **12**, 975-991, doi:10.4251/wjgo.v12.i9.975 (2020).
- 45 Jiang, T. *et al.* FNDC1 Promotes the Invasiveness of Gastric Cancer via Wnt/ β -Catenin Signaling Pathway and Correlates With Peritoneal Metastasis and Prognosis. *Frontiers in oncology* **10**, 590492, doi:10.3389/fonc.2020.590492 (2020).

- 46 Liu, Y. P., Chen, W. D., Li, W. N. & Zhang, M. Overexpression of FNDC1 Relates to Poor Prognosis and Its Knockdown Impairs Cell Invasion and Migration in Gastric Cancer. *Technology in cancer research & treatment* **18**, 1533033819869928, doi:10.1177/1533033819869928 (2019).
- 47 Zhong, M. *et al.* High FNDC1 expression correlates with poor prognosis in gastric cancer. *Experimental and therapeutic medicine* **16**, 3847-3854, doi:10.3892/etm.2018.6731 (2018).
- 48 Ren, J. *et al.* Overexpression of FNDC1 in Gastric Cancer and its Prognostic Significance. *Journal of Cancer* **9**, 4586-4595, doi:10.7150/jca.27672 (2018).





Figure 1. A: Heat maps of 24 circRNAs with significant differences; B: Heat maps of 91 miRNAs with significant differences; C: Heat maps of 114 significantly different mRNAs.



medRxiv preprint doi: <https://doi.org/10.1101/2023.08.01.23293496>; this version posted August 4, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).


Figure 2.1 Structure diagram of part circRNA;



medRxiv preprint doi: <https://doi.org/10.1101/2023.08.01.23293496>; this version posted August 4, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

Figure 3. ccRNA network diagram built via Cytoscape 3.8.0.


hsa_circ_0007404



hsa_circ_0007613



hsa_circ_0008615




hsa_circ_0008768



hsa_circ_0034398



hsa_circ_0045602




medRxiv preprint doi: <https://doi.org/10.1101/2023.08.01.23293496>; this version posted August 4, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

hsa_circ_0052001



hsa_circ_0055521



hsa_circ_0088485



hsa_circ_0051246



Figure 2.2 Structure diagram of partial circRNA;

A



medRxiv preprint doi: <https://doi.org/10.1101/2023.08.01.23293496>; this version posted August 4, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

B




Figure 2.3 A: miRNA.diff and MRE are intersected by Venn diagram; B: target and mRNA.diff looks for mRNA that is co-expressed.





Figure 4.1 A: circRNA heat map of ceRNA network; B: miRNA heat map of ceRNA network.





Figure 4.2 mRNA heat map of ceRNA network.

A



B




Figure 4.3 A: circRNA box diagram of ceRNA network; B: miRNA box diagram of ceRNA network.




Figure 4.4 mRNA box diagram of ceRNA network.

medRxiv preprint doi: <https://doi.org/10.1101/2023.08.01.23293496>; this version posted August 4, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).




Figure 5.1 BP enrichment map for GO analysis of mRNA constituting ceRNA network.

medRxiv preprint doi: <https://doi.org/10.1101/2023.08.01.23293496>; this version posted August 4, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).




Figure 5.2 CC enrichment map for GO analysis of mRNA constituting ceRNA network.

medRxiv preprint doi: <https://doi.org/10.1101/2023.08.01.23293496>; this version posted August 4, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).




Figure 5.3 MF enrichment diagram for GO analysis of mRNA constituting ceRNA network.




Figure 5.4 Pathway map for KEGG enrichment analysis of mRNA constituting ceRNA network.

Table 1. The top 20 BP results of GO analysis.

ID	Description	pvalue	geneID
	negative regulation of ion transport	4.17E-06	PTGS2/SFRP4/MMP9/GEM
	regulation of transmembrane receptor protein serine/threonine kinase signaling pathway	3.56E-05	SULF1/SFRP4/CILP/ASPN
	transmembrane receptor protein serine/threonine kinase signaling pathway	0.000123768	SULF1/SFRP4/CILP/ASPN
	positive regulation of vascular endothelial growth factor production	0.000206688	SULF1/PTGS2
	negative regulation of ion transport	0.000301177	PTGS2/SFRP4/MMP9/GEM
	regulation of neuroinflammatory response	0.000415322	PTGS2/MMP9
	collagen catabolic process	0.000435902	MMP9/FAP
	response to tumor necrosis factor	0.000750016	PTGS2/CHI3L1/CCL18
	negative regulation of endopeptidase activity	0.000767632	PTGS2/SPOCK1/MMP9
	regulation of calcium ion transport	0.000767632	PTGS2/GEM/THY1
	embryo implantation	0.000802875	PTGS2/MMP9
	negative regulation of cation channel activity	0.000802875	MMP9/GEM
	regulation of vascular endothelial growth factor production	0.000859994	SULF1/PTGS2
	negative regulation of peptidase activity	0.000869263	PTGS2/SPOCK1/MMP9
	extracellular matrix disassembly	0.000949255	MMP9/FAP
	vascular endothelial growth factor production	0.000979961	SULF1/PTGS2
	negative regulation of calcium ion transport	0.001107533	PTGS2/GEM
	neuroinflammatory response	0.001313061	PTGS2/MMP9
	extracellular matrix organization	0.001373366	SULF1/MMP9/FAP
	extracellular structure organization	0.001386263	SULF1/MMP9/FAP

medRxiv preprint doi: <https://doi.org/10.1101/2023.08.01.23293496>; this version posted August 4, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

Table2. The top 20 CC results of GO analysis.

ID	Description	pvalue	geneID
	collagen-containing extracellular matrix	1.23E-05	SULF1/THBS2/MMP9/ CILP/ASPN
	main axon	0.000975247	SPOCK1/THY1
	membrane raft	0.001789774	SULF1/PTGS2/THY1
	membrane microdomain	0.001805514	SULF1/PTGS2/THY1
	leading edge membrane	0.007715433	THY1/FAP
	axolemma	0.009909463	THY1
	node of Ranvier	0.011425836	SPOCK1
	anchored component of external side of plasma membrane	0.01520729	THY1
	lamellipodium membrane	0.016716088	FAP
	intrinsic component of external side of plasma membrane	0.018222729	THY1
	neuronal cell body membrane	0.021229548	THY1
	nuclear outer membrane	0.021979909	PTGS2
	cell body membrane	0.02347902	THY1
	cell projection membrane	0.027010044	THY1/FAP
	spindle midzone	0.027217419	GEM
	dendrite membrane	0.030942458	THY1
	cell leading edge	0.039342466	THY1/FAP
	focal adhesion	0.039860127	THY1/FAP
	apical part of cell	0.040728808	THY1/FAP
	tertiary granule lumen	0.04130	MMP9

medRxiv preprint doi: <https://doi.org/10.1101/2023.08.01.23293496>; this version posted August 4, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

Table3. The top 20 MF results of GO analysis.

ID	Description	pvalue	geneID
	extracellular matrix structural constituent	6.85E-06	CHI3L1/THBS2/CILP/ASPN
	collagen binding	0.001188741	MMP9/ASPN
	integrin binding	0.006072574	THY1/FAP
	serine-type endopeptidase activity	0.007501046	MMP9/FAP
	dipeptidyl-peptidase activity	0.007580439	FAP
	serine-type peptidase activity	0.008976615	MMP9/FAP
	serine hydrolase activity	0.009341335	MMP9/FAP
	arylsulfatase activity	0.010597647	SULF1
	metalloendopeptidase inhibitor activity	0.012103054	SPOCK1
	sulfuric ester hydrolase activity	0.01285496	SULF1
	glycosaminoglycan binding	0.013237474	SULF1/THBS2
	extracellular matrix structural constituent conferring compression resistance	0.016606525	ASPN
	oxidoreductase activity, acting on single donors with incorporation of molecular oxygen, incorporation of two atoms of oxygen	0.01810344	PTGS2
	oxidoreductase activity, acting on single donors with incorporation of molecular oxygen	0.018851105	PTGS2
	glycolipid binding	0.021836478	THY1
	Wnt-protein binding	0.022581502	SFRP4

medRxiv preprint doi: <https://doi.org/10.1101/2023.08.01.23293496>; this version posted August 4, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

calcium channel regulator activity	0.032218989	GEM
CCR chemokine receptor binding	0.03516657	CCL18
chemokine activity	0.036637232	CCL18
peroxidase activity	0.038839323	PTGS2

Table 4. The results of KEGG analysis.

ID	Description	pvalue	geneID
	IL-17 signaling pathway	0.001896872	PTGS2/MMP9
	TNF signaling pathway	0.002681694	PTGS2/MMP9
	leukocyte transendothelial migration	0.002776944	MMP9/THY1
	MicroRNAs in cancer	0.019359176	PTGS2/MMP9
	Human papillomavirus infection	0.021922529	PTGS2/THBS2
	Bladder cancer	0.029668581	MMP9
	Malaria	0.036082009	THBS2
	Ovarian steroidogenesis	0.036792427	PTGS2
	Regulation of lipolysis in adipocytes	0.041753142	PTGS2
	VEGF signaling pathway	0.042460074	PTGS2
	Arachidonic acid metabolism	0.043872635	PTGS2
	Chemical carcinogenesis - DNA adducts	0.049505527	PTGS2

medRxiv preprint doi: <https://doi.org/10.1101/2023.08.01.23293496>; this version posted August 4, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).





Figure 6.1 ceRNA networks associated with the prognosis of gastric cancer.

A



medRxiv preprint doi: <https://doi.org/10.1101/2023.08.01.23293496>; this version posted August 4, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

B





Figure 6.2 A: Survival analysis of target gene FAP, $P < 0.05$; B: Survival analysis of target gene FNDC1, $P < 0.05$.

FAP

FNDC1

T



medRxiv preprint doi: <https://doi.org/10.1101/2023.08.01.23293496>; this version posted August 4, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

N




Figure 7. Immunohistochemical profiles of target genes FAP and FNDC1 based on HPA database.